{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:12:39Z","timestamp":1792566759540,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1093\/neuonc\/not242","type":"journal-article","created":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T02:01:42Z","timestamp":1389405702000},"page":"493-504","source":"Crossref","is-referenced-by-count":82,"title":["mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma"],"prefix":"10.1093","volume":"16","author":[{"given":"Marco","family":"Giovannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas-Xavier","family":"Bonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Vitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Chareyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel M.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Valeyrie-Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Goutagny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Kalamarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"issue":"Suppl 5","key":"key\n\t\t\t\t20170508181109_NOT242C1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro Oncol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C2","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q J Med"},{"key":"key\n\t\t\t\t20170508181109_NOT242C3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2012","journal-title":"Am J Med Genet A"},{"key":"key\n\t\t\t\t20170508181109_NOT242C4","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1038\/onc.2010.363","article-title":"Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas","volume":"29","author":"Hadfield","year":"2010","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170508181109_NOT242C5","first-page":"1649","article-title":"Universal absence of merlin, but not other ERM family members, in schwannomas","volume":"151","author":"Stemmer-Rachamimov","year":"1997","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2009.02.006","article-title":"Merlin and the ERM proteins\u2014regulators of receptor distribution and signaling at the cell cortex","volume":"19","author":"McClatchey","year":"2009","journal-title":"Trends Cell Biol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/embor.2012.11","article-title":"Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus","volume":"13","author":"Li","year":"2012","journal-title":"EMBO Rep"},{"key":"key\n\t\t\t\t20170508181109_NOT242C8","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C9","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2217\/fnl.12.45","article-title":"mTOR as a potential treatment target for epilepsy","volume":"7","author":"Wong","year":"2012","journal-title":"Future Neurol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev"},{"issue":"Spec No. 2","key":"key\n\t\t\t\t20170508181109_NOT242C12","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1093\/hmg\/ddi260","article-title":"Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways","volume":"14","author":"Kwiatkowski","year":"2005","journal-title":"Human Mol Genet"},{"key":"key\n\t\t\t\t20170508181109_NOT242C13","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/era.11.93","article-title":"Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis","volume":"11","author":"Franz","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"key\n\t\t\t\t20170508181109_NOT242C14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170508181109_NOT242C15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170508181109_NOT242C16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molcel.2010.05.017","article-title":"Structure of the human mTOR complex I and its implications for rapamycin inhibition","volume":"38","author":"Yip","year":"2010","journal-title":"Mol Cell"},{"key":"key\n\t\t\t\t20170508181109_NOT242C17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin","volume":"10","author":"Phung","year":"2006","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170508181109_NOT242C18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"key\n\t\t\t\t20170508181109_NOT242C19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170508181109_NOT242C20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2\u2013deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol Cancer Res"},{"key":"key\n\t\t\t\t20170508181109_NOT242C21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1101\/gad.13.8.978","article-title":"Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein","volume":"13","author":"Giovannini","year":"1999","journal-title":"Genes Dev"},{"key":"key\n\t\t\t\t20170508181109_NOT242C22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","article-title":"User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability","volume":"31","author":"Yushkevich","year":"2006","journal-title":"NeuroImage"},{"key":"key\n\t\t\t\t20170508181109_NOT242C23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/MCB.22.4.1150-1157.2002","article-title":"The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells","volume":"22","author":"Bashour","year":"2002","journal-title":"Mol Cell Biol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C24","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.onc.1202141","article-title":"Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells","volume":"17","author":"Pelton","year":"1998","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170508181109_NOT242C25","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-03-4079","article-title":"Comparative pathology of nerve sheath tumors in mouse models and humans","volume":"64","author":"Stemmer-Rachamimov","year":"2004","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20170508181109_NOT242C26","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-12-3167","article-title":"Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2","volume":"19","author":"Tanaka","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170508181109_NOT242C27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-9-8","article-title":"Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Pharmacol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C28","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20170508181109_NOT242C29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1073\/pnas.0510857103","article-title":"Cancer-specific mutations in PIK3CA are oncogenic in vivo","volume":"103","author":"Bader","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20170508181109_NOT242C30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.101.4.1","article-title":"Combination therapy of inhibitors of epidermal growth factor receptor\/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition","volume":"4","author":"Goudar","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"key\n\t\t\t\t20170508181109_NOT242C31","first-page":"1540","article-title":"Serial follow-up MR imaging after gamma knife radiosurgery for vestibular schwannoma","volume":"21","author":"Nakamura","year":"2000","journal-title":"Am J Neuroradiol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C32","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C33","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1101\/gad.1335605","article-title":"Membrane organization and tumorigenesis\u2014the NF2 tumor suppressor, Merlin","volume":"19","author":"McClatchey","year":"2005","journal-title":"Genes Dev"},{"key":"key\n\t\t\t\t20170508181109_NOT242C34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"key\n\t\t\t\t20170508181109_NOT242C35","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170508181109_NOT242C36","first-page":"91","article-title":"Neurofibromatosis type 2","volume":"70","author":"Evans","year":"2011","journal-title":"Adv Otorhinolaryngol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C37","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","article-title":"mTORC1 inhibitors suppress meningioma growth in mouse models","volume":"19","author":"Pachow","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170508181109_NOT242C38","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","article-title":"Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas","volume":"11","author":"Mawrin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170508181109_NOT242C39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1227\/NEU.0b013e31828bae28","article-title":"Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results","volume":"72","author":"Peyre","year":"2013","journal-title":"Neurosurgery"},{"key":"key\n\t\t\t\t20170508181109_NOT242C40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"0000","journal-title":"Neuro Oncol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170508181109_NOT242C42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","article-title":"Long-term natural history of neurofibromatosis type 2\u2013associated intracranial tumors","volume":"117","author":"Dirks","year":"2012","journal-title":"J Neurosurg"},{"key":"key\n\t\t\t\t20170508181109_NOT242C43","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/neuonc\/nos129","article-title":"Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features","volume":"14","author":"Goutagny","year":"2012","journal-title":"Neuro Oncol"},{"key":"key\n\t\t\t\t20170508181109_NOT242C44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature10937","article-title":"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response","volume":"483","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170508181109_NOT242C45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/ng.2650","article-title":"A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer","volume":"45","author":"Lunardi","year":"2013","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170508181109_NOT242C46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-11-0061","article-title":"The APL paradigm and the \u201cco-clinical trial\u201d project","volume":"1","author":"Nardella","year":"2011","journal-title":"Cancer Disc"},{"key":"key\n\t\t\t\t20170508181109_NOT242C47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ccr.2006.10.001","article-title":"AKT and cancer\u2014is it all mTOR?","volume":"10","author":"Rosen","year":"2006","journal-title":"Cancer Cell"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/16\/4\/493\/16664678\/not242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T19:03:34Z","timestamp":1688929414000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/not242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/not242","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,10]]}}}